Rein Therapeutics (RNTX) Income from Continuing Operations (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Income from Continuing Operations of 5549000.0 for Q1 2026, up 15.5% year-over-year from 4804256.16 in Q1 2025, and up 83.08% quarter-over-quarter from 32799000.0 in Q4 2025.
Rein Therapeutics (RNTX) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Income from Continuing Operations for 11 consecutive years, with 5549000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 15.5% year-over-year to 5549000.0; the TTM figure through Mar 2026 stood at 51301000.0 (up 48.99% YoY), while the FY2025 annual figure was 50728000.0, up 38.16% from the prior year.
- Income from Continuing Operations advanced to 5549000.0 in Q1 2026 per RNTX's latest filing, from 32799000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1981000.0 in Q3 2023 and bottomed at 82094000.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 18124176.47 across 5 years, with a median of 8168000.0 in 2022.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations jumped 75.69% — and 2024, when it plunged 469.13%.
- Rein Therapeutics' Income from Continuing Operations stood at 82094000.0 in 2022, then jumped by 68.58% to 25796000.0 in 2023, then sank by 183.93% to 73243000.0 in 2024, then surged by 55.22% to 32799000.0 in 2025, then jumped by 83.08% to 5549000.0 in 2026.
- Business Quant data shows RNTX's Income from Continuing Operations at 5549000.0 in Q1 2026, 32799000.0 in Q4 2025, and 5645000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | -6.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.55 Mn |
| Mar 31, 2026 | -5.55 Mn |
| Dec 31, 2025 | -32.80 Mn |
| Sep 30, 2025 | -5.65 Mn |
| Jun 30, 2025 | -7.31 Mn |
| Mar 31, 2025 | -6.57 Mn |
| Dec 31, 2024 | -73.24 Mn |
| Sep 30, 2024 | -9.45 Mn |
| Jun 30, 2024 | -11.30 Mn |
| Mar 31, 2024 | -16.10 Mn |
| Dec 31, 2023 | -25.80 Mn |
| Sep 30, 2023 | -1.98 Mn |
| Jun 30, 2023 | -1.99 Mn |
| Mar 31, 2023 | -4.98 Mn |
| Dec 31, 2022 | -82.09 Mn |
| Sep 30, 2022 | -6.58 Mn |
| Jun 30, 2022 | -8.17 Mn |
| Mar 31, 2022 | -8.56 Mn |
| Dec 31, 2021 | -76.51 Mn |
| Sep 30, 2021 | -7.24 Mn |